---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-133141"
form_type: "8-K"
ticker: null
cik: "0001827087"
company_name: "Vigil Neuroscience, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:51:27.940690+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vigil Neuroscience reports Q1 net loss $19.9M; completes enrollment for Phase 2 ALSP trial, data in Q3 2024

## Summary
- Cash, cash equivalents & marketable securities $101.6M as of Mar 31, 2024; expected to fund operations into H2 2025.
- Completed enrollment for Phase 2 IGNITE trial of iluzanebart in ALSP with 20 patients, exceeding planned 15.
- Next data readout from Phase 2 IGNITE planned for Q3 2024, including 12-month data from 20 mg/kg cohort and 6-month from 40 mg/kg.
- Phase 1 trial of VG-3927 for Alzheimer's ongoing; interim healthy volunteer data expected mid-2024.
- Appointed Petra Kaufmann as Chief Medical Officer; she brings over 25 years of neurology drug development experience.

## SEC filing metadata
- accession: 0001193125-24-133141
- form_type: 8-K
- cik: 0001827087
- company_name: Vigil Neuroscience, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827087/000119312524133141/0001193125-24-133141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827087/000119312524133141/d825217d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-133141
- JSON: https://secwatch.observer/filing/0001193125-24-133141.json
- Plain text: https://secwatch.observer/filing/0001193125-24-133141.txt

## Key facts
- Earnings Releases
  Vigil Neuroscience, Inc. reported First quarter ended March 31, 2024 results: net income Loss from operations for the first quarter ended March 31, 2024 were $19.9 million.
  - Period: First quarter ended March 31, 2024
  - Net income: Loss from operations for the first quarter ended March 31, 2024 were $19.9 million
  - Result: reported results
  source text: Loss from operations for the first quarter ended March 31, 2024 were $19.9 million, compared to $19.8 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827087/000119312524133141/0001193125-24-133141-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.